دورية أكاديمية
أعرض في EDS

Deficit of circulating CD19 + CD24 hi CD38 hi regulatory B cells in severe aplastic anaemia.

التفاصيل البيبلوغرافية
العنوان: Deficit of circulating CD19 + CD24 hi CD38 hi regulatory B cells in severe aplastic anaemia.
المؤلفون: Zaimoku Y; Hematology Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA., Patel BA; Hematology Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA., Kajigaya S; Hematology Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA., Feng X; Hematology Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA., Alemu L; Hematology Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA., Quinones Raffo D; Hematology Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA., Groarke EM; Hematology Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA., Young NS; Hematology Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA.
المصدر: British journal of haematology [Br J Haematol] 2020 Aug; Vol. 190 (4), pp. 610-617. Date of Electronic Publication: 2020 Apr 20.
نوع المنشور: Journal Article; Research Support, N.I.H., Intramural
اللغة: English
بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE
أسماء مطبوعة: Publication: Oxford : Wiley-Blackwell
Original Publication: Oxford : Blackwell Scientific Publications
مواضيع طبية MeSH: ADP-ribosyl Cyclase 1/*analysis , Anemia, Aplastic/*blood , Antigens, CD19/*analysis , B-Lymphocyte Subsets/*pathology , B-Lymphocytes, Regulatory/*pathology , CD24 Antigen/*analysis , Lymphopenia/*etiology , Membrane Glycoproteins/*analysis, Adolescent ; Adult ; Aged ; Anemia, Aplastic/complications ; Anemia, Aplastic/drug therapy ; Anemia, Aplastic/pathology ; Antilymphocyte Serum/therapeutic use ; B-Lymphocyte Subsets/chemistry ; B-Lymphocytes, Regulatory/chemistry ; Benzoates/therapeutic use ; Bone Marrow/pathology ; CD4-Positive T-Lymphocytes/pathology ; CD8-Positive T-Lymphocytes/pathology ; Cyclosporine/therapeutic use ; Female ; Humans ; Hydrazines/therapeutic use ; Immunosuppressive Agents/therapeutic use ; Interleukin-10/biosynthesis ; Interleukin-10/genetics ; Killer Cells, Natural/pathology ; Lymphocyte Count ; Lymphopenia/blood ; Lymphopenia/pathology ; Male ; Middle Aged ; Pyrazoles/therapeutic use ; Receptors, Thrombopoietin/agonists ; Young Adult
مستخلص: Immune aplastic anaemia (AA) is caused by cytotoxic T lymphocytes (CTLs) that destroy haematopoietic stem and progenitor cells. Enhanced type 1 T helper (Th1) responses and reduced regulatory T cells (Tregs) are involved in the immune pathophysiology. CD24 hi CD38 hi regulatory B cells (Bregs) suppress CTLs and Th1 responses, and induce Tregs via interleukin 10 (IL-10). We investigated circulating B-cell subpopulations, including CD24 hi CD38 hi Bregs, as well as total B cells, CD4 + T cells, CD8 + T cells and natural killer cells in 104 untreated patients with severe and very severe AA, aged ≥18 years. All patients were treated with standard immunosuppressive therapy (IST) plus eltrombopag. CD24 hi CD38 hi Bregs were markedly reduced in patients with AA compared to healthy individuals, especially in very severe AA, but residual Bregs remained functional, capable of producing IL-10; total B-cell counts and the other B-cell subpopulations were similar to those of healthy individuals. CD24 hi CD38 hi Bregs did not correlate with responses to IST, and they recovered to levels present in healthy individuals after therapy. Mature naïve B-cell counts were unexpectedly associated with IST response. Markedly reduced CD24 hi CD38 hi Bregs, especially in very severe AA, with recovery after IST suggest Breg deficits may contribute to the pathophysiology of immune AA.
(Published 2020. This article is a U.S. Government work and is in the public domain in the USA. British Journal of Haematology published by British Society of Haematology and John Wiley & Sons Ltd.)
التعليقات: Comment in: Br J Haematol. 2020 Aug;190(4):486-487. (PMID: 32583450)
References: Blood. 2011 Dec 15;118(25):6601-9. (PMID: 21963603)
Blood. 2014 Sep 25;124(13):2034-45. (PMID: 25051962)
Br J Haematol. 2004 Sep;126(5):682-5. (PMID: 15327519)
J Immunol. 2016 Feb 15;196(4):1568-78. (PMID: 26764034)
N Engl J Med. 2018 Oct 25;379(17):1643-1656. (PMID: 30354958)
J Immunol. 1985 Oct;135(4):2502-6. (PMID: 3928752)
Sci Transl Med. 2013 Feb 20;5(173):173ra23. (PMID: 23427243)
Immunology. 2009 Apr;126(4):458-65. (PMID: 19278419)
Immunity. 2012 Mar 23;36(3):477-90. (PMID: 22406267)
Blood. 2019 May 9;133(19):2043-2055. (PMID: 30803992)
Blood. 2017 May 25;129(21):2908-2916. (PMID: 28232583)
Blood. 2007 Sep 1;110(5):1603-6. (PMID: 17463169)
Haematologica. 2018 May;103(5):759-769. (PMID: 29419434)
Life Sci. 2017 Nov 15;189:71-75. (PMID: 28935248)
J Immunol. 2009 Mar 15;182(6):3414-22. (PMID: 19265119)
Blood Adv. 2018 Feb 27;2(4):390-400. (PMID: 29472446)
Lancet. 2004 Jul 24-30;364(9431):355-64. (PMID: 15276395)
J Clin Invest. 2017 Mar 1;127(3):772-779. (PMID: 28248202)
J Leukoc Biol. 2013 May;93(5):811-8. (PMID: 23434518)
J Exp Med. 1986 Jul 1;164(1):263-79. (PMID: 3088195)
Immunity. 2010 Jan 29;32(1):129-40. (PMID: 20079667)
Front Immunol. 2016 Aug 29;7:330. (PMID: 27621733)
Blood. 1986 May;67(5):1349-55. (PMID: 3083891)
Blood Adv. 2017 Oct 10;1(22):1900-1910. (PMID: 28971166)
N Engl J Med. 1985 Jan 31;312(5):257-65. (PMID: 2981406)
Leukemia. 2014 Jan;28(1):192-5. (PMID: 23787393)
N Engl J Med. 2017 Apr 20;376(16):1540-1550. (PMID: 28423296)
Bone Marrow Transplant. 2013 Mar;48(3):452-8. (PMID: 23208313)
Blood. 2006 May 15;107(10):3983-91. (PMID: 16434488)
Blood. 2012 Oct 18;120(16):3318-25. (PMID: 22859611)
Eur J Haematol. 2009 Dec 1;83(6):503-11. (PMID: 19686268)
Cell Stem Cell. 2014 Apr 3;14(4):486-499. (PMID: 24702997)
Blood. 2015 Dec 10;126(24):2621-31. (PMID: 26491068)
Blood Adv. 2018 Jan 23;2(2):126-141. (PMID: 29365321)
Blood. 2016 Sep 1;128(9):1193-205. (PMID: 27281795)
J Leukoc Biol. 1985 Aug;38(2):231-9. (PMID: 3875675)
N Engl J Med. 2015 Jul 2;373(1):35-47. (PMID: 26132940)
Blood. 2014 Dec 11;124(25):3699-708. (PMID: 25342713)
Br J Haematol. 2009 Jan;144(2):206-16. (PMID: 19036108)
Proc Natl Acad Sci U S A. 1985 Jan;82(1):188-92. (PMID: 3918301)
N Engl J Med. 2011 Aug 4;365(5):430-8. (PMID: 21812672)
Rev Assoc Med Bras (1992). 2019 Jun 03;65(5):637-646. (PMID: 31166440)
PLoS One. 2016 Apr 05;11(4):e0153170. (PMID: 27045291)
معلومات مُعتمدة: ZIA HL002315 United States ImNIH Intramural NIH HHS; United States HL NHLBI NIH HHS
فهرسة مساهمة: Keywords: aplastic anaemia; flow cytometry; immunosuppressive therapy; lymphocyte subsets; regulatory B cells
المشرفين على المادة: 0 (Antigens, CD19)
0 (Antilymphocyte Serum)
0 (Benzoates)
0 (CD19 molecule, human)
0 (CD24 Antigen)
0 (CD24 protein, human)
0 (Hydrazines)
0 (IL10 protein, human)
0 (Immunosuppressive Agents)
0 (Membrane Glycoproteins)
0 (Pyrazoles)
0 (Receptors, Thrombopoietin)
130068-27-8 (Interleukin-10)
143641-95-6 (MPL protein, human)
83HN0GTJ6D (Cyclosporine)
EC 3.2.2.5 (CD38 protein, human)
EC 3.2.2.6 (ADP-ribosyl Cyclase 1)
S56D65XJ9G (eltrombopag)
تواريخ الأحداث: Date Created: 20200421 Date Completed: 20210304 Latest Revision: 20221005
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC7496711
DOI: 10.1111/bjh.16651
PMID: 32311088
قاعدة البيانات: MEDLINE
الوصف
تدمد:1365-2141
DOI:10.1111/bjh.16651